Format

Send to

Choose Destination
Hum Vaccin Immunother. 2019 Jul 24:1-3. doi: 10.1080/21645515.2019.1636598. [Epub ahead of print]

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.

Author information

1
a TIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
2
b Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
3
c Department of Mathematical Sciences, Chalmers University of Technology , Gothenburg , Sweden.
4
d Department of Laboratory Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.

Abstract

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.

KEYWORDS:

Acute myeloid leukemia; IL-2; histamine dihydrochloride; immunotherapy; normal karyotype; relapse prevention

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center